Ocugen Inc (OCGN)

Feb 06, 2026

Ocugen grants CEO new performance-based equity award - MSN

Feb 06, 2026

Feb 06, 2026

Wall Street Recap: Can Ocugen Inc be recession proof2025 Price Action Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Feb 06, 2026

Feb 06, 2026

Breakout Move: Will Ocugen Inc stock recover after earningsJuly 2025 Levels & Real-Time Market Trend Scan - baoquankhu1.vn

Feb 06, 2026

Feb 05, 2026

Ocugen’s Gene Therapy Progress and Funding Extend Runway - AD HOC NEWS

Feb 05, 2026

Feb 05, 2026

Ocugen Shares Stabilize Following Recent Equity Offering - AD HOC NEWS

Feb 05, 2026

Feb 03, 2026

Trade Report: Can Ocugen Inc be recession proofWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn

Feb 03, 2026

Feb 03, 2026

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN

Feb 03, 2026

Feb 01, 2026

Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MSN

Feb 01, 2026

Feb 01, 2026

Ocugen prices $22.5M common stock offering at $1.50 per share - MSN

Feb 01, 2026

Jan 31, 2026

What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn

Jan 31, 2026

Jan 31, 2026

Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026

RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn

Jan 30, 2026

Jan 30, 2026

Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS

Jan 30, 2026

Jan 29, 2026

Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive

Jan 29, 2026

Jan 29, 2026

Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial - CGTLive®

Jan 29, 2026

Jan 28, 2026

Ocugen stock surges 75% year to date: What's in store for 2026? - MSN

Jan 28, 2026

Jan 28, 2026

Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 - MyChesCo

Jan 28, 2026

Jan 28, 2026

Macro Review: Is Ocugen Inc forming a double bottom2025 Volatility Report & Growth Oriented Trading Recommendations - baoquankhu1.vn

Jan 28, 2026

Jan 28, 2026

Ocugen Stock: A Turnaround Fueled by Promising Trial Data - AD HOC NEWS

Jan 28, 2026

Jan 27, 2026

Ocugen’s Clinical Pipeline Takes Center Stage Following Capital Raise - AD HOC NEWS

Jan 27, 2026

Jan 27, 2026

How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance

Jan 27, 2026

Jan 27, 2026

Ocugen Secures Financial Runway Through Strategic Capital Raise - AD HOC NEWS

Jan 27, 2026

Jan 27, 2026

Ocugen Secures Funding to Advance Gene Therapy Pipeline - AD HOC NEWS

Jan 27, 2026

Jan 26, 2026

Ocugen Secures Funding at a Short-Term Cost to Shareholders - AD HOC NEWS

Jan 26, 2026

Jan 24, 2026

Ocugen Shares Defy Dilution Fears on Strong Clinical Data - AD HOC NEWS

Jan 24, 2026

Jan 24, 2026

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - Sahm

Jan 24, 2026

Jan 24, 2026

Ocugen closes $22.5 million registered direct offering By Investing.com - Investing.com South Africa

Jan 24, 2026

Jan 23, 2026

Ocugen Secures Financial Runway Through 2026 - AD HOC NEWS

Jan 23, 2026

Jan 23, 2026

How Fresh Capital And Positive OCU410 Data At Ocugen (OCGN) Has Changed Its Investment Story - Yahoo Finance

Jan 23, 2026

Jan 23, 2026

Ocugen strengthens balance sheet with new equity financing - TipRanks

Jan 23, 2026

Jan 23, 2026

Ocugen, Inc. Closes $22.5 Million Stock Offering - TradingView

Jan 23, 2026

Jan 23, 2026

Ocugen closes $22.5 million registered direct offering - Investing.com

Jan 23, 2026

Jan 23, 2026

Ocugen (NASDAQ: OCGN) reports strong midstage data for gene therapy - MSN

Jan 23, 2026

Jan 22, 2026

Ocugen Announces $22.5 Million Public Stock Offering - The Globe and Mail

Jan 22, 2026

Jan 22, 2026

Ocugen (NASDAQ:OCGN) Trading 12.4% HigherTime to Buy? - MarketBeat

Jan 22, 2026

Jan 22, 2026

Ocugen Stock Faces Dilution After Capital Raise - AD HOC NEWS

Jan 22, 2026

Jan 22, 2026

Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy - MyChesCo

Jan 22, 2026

Jan 22, 2026

Ocugen prices $22.5 million common stock offering at $1.50 per share - Investing.com Nigeria

Jan 22, 2026

Jan 22, 2026

Ocugen prices $22.5 million common stock offering at $1.50 per share By Investing.com - Investing.com South Africa

Jan 22, 2026

Jan 21, 2026

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN

Jan 21, 2026

Jan 21, 2026

Ocugen Signs Underwriting Agreement With Oppenheimer & Co - TradingView

Jan 21, 2026

Jan 21, 2026

Form 424B5 Ocugen, Inc. - StreetInsider

Jan 21, 2026

Jan 21, 2026

Ocugen shares slide after company prices $22.5 million equity raise - MSN

Jan 21, 2026

Jan 21, 2026

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Ocugen, Inc.

Jan 21, 2026

Jan 21, 2026

Ocugen (OCGN) Prices $22.5 Million Stock Offering - GuruFocus

Jan 21, 2026

Jan 21, 2026

Ocugen drops on stock offering - TradingView

Jan 21, 2026

Jan 21, 2026

Ocugen (OCGN) Prices Stock Offering to Raise $22.5 Million - GuruFocus

Jan 21, 2026

Jan 21, 2026

Ocugen stock falls after pricing $22.5 million common share offering By Investing.com - Investing.com Nigeria

Jan 21, 2026